Comparative Pharmacology
Head-to-head clinical analysis: ADENOSCAN versus ETHMOZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSCAN versus ETHMOZINE.
ADENOSCAN vs ETHMOZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is a purine nucleoside that acts as a coronary vasodilator by activating A2A adenosine receptors on vascular smooth muscle, causing hyperemia. It also slows atrioventricular (AV) nodal conduction via A1 receptor activation.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
Intravenous administration at 140 mcg/kg/min for 6 minutes (total dose 0.84 mg/kg).
200-300 mg orally every 8 hours; maximum 900 mg/day.
None Documented
None Documented
< 10 seconds (biphasic: distribution half-life < 1 second, terminal elimination half-life ~0.6-1.5 seconds). Clinically, effects are rapidly terminated due to cellular uptake and metabolism.
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Primarily renal excretion of metabolites; <3% excreted unchanged in urine. Adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with further degradation to uric acid. <2% eliminated in feces.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Category C
Category C
Antiarrhythmic
Antiarrhythmic